Enclomifene

Enclomifene (INN, USAN) (developmental code names GTx-758, RMI-16289), also known as enclomiphene (BAN), is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that is under development for the treatment of hypogonadism and breast cancer.

Pharmacology[edit | edit source]

Enclomifene is a SERM, or an anti-estrogen, which decreases the effect of estrogen in the body. It is the trans-isomer of clomifene (clomiphene). Enclomifene constitutes about 70% of the mixture in clomifene, with the remaining 30% being composed of its cis-isomer, zuclomifene.

Medical Uses[edit | edit source]

Enclomifene is used for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. It is also being developed for use in the treatment of men with low testosterone levels who wish to preserve their fertility.

Side Effects[edit | edit source]

The most common side effects of enclomifene include headache, nausea, and in some cases, visual disturbances. These side effects are generally mild and temporary.

Development[edit | edit source]

Enclomifene was developed by GTx, Inc., a biopharmaceutical company based in Memphis, Tennessee. It is currently in the late stages of clinical development.

References[edit | edit source]

Enclomifene Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.